Add to ORKGBackground: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etoposide) and carbo-platin is an effective and safe first-line treatment for patients with small-cell lung cancer (SCLC). We conducted a ran-domized phase III multicenter trial to determine whether paclitaxel plus etoposide plus carboplatin improves the out-come of patients with primary SCLC relative to standard chemotherapy (carboplatin, etoposide, and vincristine)
Back Ground: Non small cell lung cancer (NSCLC) constitutes about 75-80 % of all lung cancer cases. ...
The EORTC Lung Cancer Cooperative group performed a randomised phase II study in patients with small...
PURPOSE: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy agai...
The progression-free survival (PFS) of cyclophosphamide/doxorubicin/etoposide (CDE) and carboplatin/...
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclita...
* See page 606 for list of participating institutions Summary Purpose: To compare the efficacy and t...
To determine, in a randomized comparison, whether the addition of paclitaxel to etoposide and cispla...
Purpose: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC...
Background: The combination of etoposide plus cisplatin (EP) is considered to be standard therapy fo...
phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic no...
Purpose: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC...
Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carb...
Free to read at publisher's site. INTRODUCTION: Performance status (PS) 2 patients with non-small ce...
Introduction:This phase III study compared efficacy and safety of topotecan-cisplatin (TP) versus to...
The EORTC Lung Cancer Cooperative group performed a randomised phase II study in patients with small...
Back Ground: Non small cell lung cancer (NSCLC) constitutes about 75-80 % of all lung cancer cases. ...
The EORTC Lung Cancer Cooperative group performed a randomised phase II study in patients with small...
PURPOSE: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy agai...
The progression-free survival (PFS) of cyclophosphamide/doxorubicin/etoposide (CDE) and carboplatin/...
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclita...
* See page 606 for list of participating institutions Summary Purpose: To compare the efficacy and t...
To determine, in a randomized comparison, whether the addition of paclitaxel to etoposide and cispla...
Purpose: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC...
Background: The combination of etoposide plus cisplatin (EP) is considered to be standard therapy fo...
phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic no...
Purpose: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC...
Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carb...
Free to read at publisher's site. INTRODUCTION: Performance status (PS) 2 patients with non-small ce...
Introduction:This phase III study compared efficacy and safety of topotecan-cisplatin (TP) versus to...
The EORTC Lung Cancer Cooperative group performed a randomised phase II study in patients with small...
Back Ground: Non small cell lung cancer (NSCLC) constitutes about 75-80 % of all lung cancer cases. ...
The EORTC Lung Cancer Cooperative group performed a randomised phase II study in patients with small...
PURPOSE: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy agai...